BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 22937757)

  • 1. Contribution of GATA1 dysfunction to multi-step leukemogenesis.
    Shimizu R; Yamamoto M
    Cancer Sci; 2012 Dec; 103(12):2039-44. PubMed ID: 22937757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GATA1 Is a Sensitive and Specific Nuclear Marker for Erythroid and Megakaryocytic Lineages.
    Lee WY; Weinberg OK; Pinkus GS
    Am J Clin Pathol; 2017 Apr; 147(4):420-426. PubMed ID: 28340113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The proto-oncogene ERG in megakaryoblastic leukemias.
    Rainis L; Toki T; Pimanda JE; Rosenthal E; Machol K; Strehl S; Göttgens B; Ito E; Izraeli S
    Cancer Res; 2005 Sep; 65(17):7596-602. PubMed ID: 16140924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GATA1-related leukaemias.
    Shimizu R; Engel JD; Yamamoto M
    Nat Rev Cancer; 2008 Apr; 8(4):279-87. PubMed ID: 18354416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of hyperproliferative fetal megakaryopoiesis by an N-terminally truncated GATA1 mutant.
    Shimizu R; Kobayashi E; Engel JD; Yamamoto M
    Genes Cells; 2009 Sep; 14(9):1119-31. PubMed ID: 19682090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A unique role of GATA1s in Down syndrome acute megakaryocytic leukemia biology and therapy.
    Xavier AC; Edwards H; Dombkowski AA; Balci TB; Berman JN; Dellaire G; Xie C; Buck SA; Matherly LH; Ge Y; Taub JW
    PLoS One; 2011; 6(11):e27486. PubMed ID: 22110660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are GATA1 mutations occurring at random in Down syndrome transient leukemia?
    Satgé D
    Med Hypotheses; 2014 Aug; 83(2):154-9. PubMed ID: 24880866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment of erythroleukemic GAK14 cells and characterization of GATA1 N-terminal domain.
    Mukai HY; Suzuki M; Nagano M; Ohmori S; Otsuki A; Tsuchida K; Moriguchi T; Ohneda K; Shimizu R; Ohneda O; Yamamoto M
    Genes Cells; 2013 Oct; 18(10):886-98. PubMed ID: 23890289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Leukemogenesis caused by dysfunctions of GATA1 transcription factor].
    Shimizu R
    Rinsho Ketsueki; 2011 Aug; 52(8):695-702. PubMed ID: 21897077
    [No Abstract]   [Full Text] [Related]  

  • 10. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.
    Greene ME; Mundschau G; Wechsler J; McDevitt M; Gamis A; Karp J; Gurbuxani S; Arceci R; Crispino JD
    Blood Cells Mol Dis; 2003; 31(3):351-6. PubMed ID: 14636651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pluripotent stem cell model of early hematopoiesis in Down syndrome reveals quantitative effects of short-form GATA1 protein on lineage specification.
    Matsuo S; Nishinaka-Arai Y; Kazuki Y; Oshimura M; Nakahata T; Niwa A; Saito MK
    PLoS One; 2021; 16(3):e0247595. PubMed ID: 33780474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nuclear interacting SET domain protein 1 inactivation impairs GATA1-regulated erythroid differentiation and causes erythroleukemia.
    Leonards K; Almosailleakh M; Tauchmann S; Bagger FO; Thirant C; Juge S; Bock T; Méreau H; Bezerra MF; Tzankov A; Ivanek R; Losson R; Peters AHFM; Mercher T; Schwaller J
    Nat Commun; 2020 Jun; 11(1):2807. PubMed ID: 32533074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcription factor GATA-1 and Down syndrome leukemogenesis.
    Muntean AG; Ge Y; Taub JW; Crispino JD
    Leuk Lymphoma; 2006 Jun; 47(6):986-97. PubMed ID: 16840187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular insights into Down syndrome-associated leukemia.
    Vyas P; Crispino JD
    Curr Opin Pediatr; 2007 Feb; 19(1):9-14. PubMed ID: 17224656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of erythroid-specific genes in megakaryoblastic disorders.
    Ito E; Kasai M; Toki T; Arai K; Yokoyama M
    Leuk Lymphoma; 1996 Nov; 23(5-6):545-50. PubMed ID: 9031085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia.
    Klusmann JH; Li Z; Böhmer K; Maroz A; Koch ML; Emmrich S; Godinho FJ; Orkin SH; Reinhardt D
    Genes Dev; 2010 Mar; 24(5):478-90. PubMed ID: 20194440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The role of GATA1 mutation in acute megakaryocytic leukemia].
    Ito E
    Rinsho Ketsueki; 2006 Nov; 47(11):1415-22. PubMed ID: 17176883
    [No Abstract]   [Full Text] [Related]  

  • 18. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.
    Cushing T; Clericuzio CL; Wilson CS; Taub JW; Ge Y; Reichard KK; Winter SS
    J Pediatr; 2006 May; 148(5):687-9. PubMed ID: 16737888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physical association of the patient-specific GATA1 mutants with RUNX1 in acute megakaryoblastic leukemia accompanying Down syndrome.
    Xu G; Kanezaki R; Toki T; Watanabe S; Takahashi Y; Terui K; Kitabayashi I; Ito E
    Leukemia; 2006 Jun; 20(6):1002-8. PubMed ID: 16628190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perturbed hematopoiesis in the Tc1 mouse model of Down syndrome.
    Alford KA; Slender A; Vanes L; Li Z; Fisher EM; Nizetic D; Orkin SH; Roberts I; Tybulewicz VL
    Blood; 2010 Apr; 115(14):2928-37. PubMed ID: 20154221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.